These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

795 related articles for article (PubMed ID: 35062368)

  • 41. Design and Evaluation of Anti-SARS-Coronavirus Agents Based on Molecular Interactions with the Viral Protease.
    Akaji K; Konno H
    Molecules; 2020 Aug; 25(17):. PubMed ID: 32867349
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Leveraging publicly available coronavirus data to identify new therapeutic targets for COVID-19.
    Sell SL; Prough DS; Weisz HA; Widen SG; Hellmich HL
    PLoS One; 2021; 16(9):e0257965. PubMed ID: 34587192
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Outcome of coronavirus spectrum infections (SARS, MERS, COVID-19) during pregnancy: a systematic review and meta-analysis.
    Di Mascio D; Khalil A; Saccone G; Rizzo G; Buca D; Liberati M; Vecchiet J; Nappi L; Scambia G; Berghella V; D'Antonio F
    Am J Obstet Gynecol MFM; 2020 May; 2(2):100107. PubMed ID: 32292902
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Emerging coronaviruses: first SARS, second MERS and third SARS-CoV-2: epidemiological updates of COVID-19.
    Halaji M; Farahani A; Ranjbar R; Heiat M; Dehkordi FS
    Infez Med; 2020 Jun; 28(suppl 1):6-17. PubMed ID: 32532933
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Limited transmissibility of coronavirus (SARS-1, MERS, and SARS-2) in certain regions of Africa.
    Ahmed AE
    J Med Virol; 2020 Oct; 92(10):1753-1754. PubMed ID: 32270498
    [No Abstract]   [Full Text] [Related]  

  • 46. Complement Activation Contributes to Severe Acute Respiratory Syndrome Coronavirus Pathogenesis.
    Gralinski LE; Sheahan TP; Morrison TE; Menachery VD; Jensen K; Leist SR; Whitmore A; Heise MT; Baric RS
    mBio; 2018 Oct; 9(5):. PubMed ID: 30301856
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Similarities and Differences of Early Pulmonary CT Features of Pneumonia Caused by SARS-CoV-2, SARS-CoV and MERS-CoV: Comparison Based on a Systemic Review.
    Chen X; Zhang G; Hao SY; Bai L; Lu JJ
    Chin Med Sci J; 2020 Sep; 35(3):254-261. PubMed ID: 32972503
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Molecular Basis of Pathogenesis of Coronaviruses: A Comparative Genomics Approach to Planetary Health to Prevent Zoonotic Outbreaks in the 21st Century.
    Asrani P; Hasan GM; Sohal SS; Hassan MI
    OMICS; 2020 Nov; 24(11):634-644. PubMed ID: 32940573
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Immune Responses to SARS-CoV, MERS-CoV and SARS-CoV-2.
    İnandıklıoğlu N; Akkoc T
    Adv Exp Med Biol; 2020; 1288():5-12. PubMed ID: 32514817
    [TBL] [Abstract][Full Text] [Related]  

  • 50. MERS-CoV endoribonuclease and accessory proteins jointly evade host innate immunity during infection of lung and nasal epithelial cells.
    Comar CE; Otter CJ; Pfannenstiel J; Doerger E; Renner DM; Tan LH; Perlman S; Cohen NA; Fehr AR; Weiss SR
    Proc Natl Acad Sci U S A; 2022 May; 119(21):e2123208119. PubMed ID: 35594398
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Impact of corticosteroid therapy on outcomes of persons with SARS-CoV-2, SARS-CoV, or MERS-CoV infection: a systematic review and meta-analysis.
    Li H; Chen C; Hu F; Wang J; Zhao Q; Gale RP; Liang Y
    Leukemia; 2020 Jun; 34(6):1503-1511. PubMed ID: 32372026
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Clinical characteristics of two human-to-human transmitted coronaviruses: Corona Virus Disease 2019 vs. Middle East Respiratory Syndrome Coronavirus.
    Xu P; Sun GD; Li ZZ
    Eur Rev Med Pharmacol Sci; 2020 May; 24(10):5797-5809. PubMed ID: 32495918
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Similarities and Dissimilarities of COVID-19 and Other Coronavirus Diseases.
    Fung TS; Liu DX
    Annu Rev Microbiol; 2021 Oct; 75():19-47. PubMed ID: 33492978
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Evaluating the role of chemokines and chemokine receptors involved in coronavirus infection.
    Olivarria G; Lane TE
    Expert Rev Clin Immunol; 2022 Jan; 18(1):57-66. PubMed ID: 34964406
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Cytokines and Lipid Mediators of Inflammation in Lungs of SARS-CoV-2 Infected Mice.
    Dubuc I; Prunier J; Lacasse É; Gravel A; Puhm F; Allaeys I; Archambault AS; Gudimard L; Villano R; Droit A; Flamand N; Boilard É; Flamand L
    Front Immunol; 2022; 13():893792. PubMed ID: 35812400
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Mast cells activated by SARS-CoV-2 release histamine which increases IL-1 levels causing cytokine storm and inflammatory reaction in COVID-19.
    Conti P; Caraffa A; Tetè G; Gallenga CE; Ross R; Kritas SK; Frydas I; Younes A; Di Emidio P; Ronconi G
    J Biol Regul Homeost Agents; 2020 Sep-Oct,; 34(5):1629-1632. PubMed ID: 32945158
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The immune response to SARS-CoV-2 and COVID-19 immunopathology - Current perspectives.
    Boechat JL; Chora I; Morais A; Delgado L
    Pulmonology; 2021; 27(5):423-437. PubMed ID: 33867315
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Innate immunity in COVID-19: Drivers of pathogenesis and potential therapeutic targets.
    Ruenjaiman V; Hirankarn N; Palaga T
    Asian Pac J Allergy Immunol; 2021 Jun; 39(2):69-77. PubMed ID: 34174806
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Influenza infection, SARS, MERS and COVID-19: Cytokine storm - The common denominator and the lessons to be learned.
    Ryabkova VA; Churilov LP; Shoenfeld Y
    Clin Immunol; 2021 Feb; 223():108652. PubMed ID: 33333256
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Immunological map in COVID-19.
    Li CH; Chiou HC; Lin MH; Kuo CH; Lin YC; Lin YC; Hung CH; Kuo CH
    J Microbiol Immunol Infect; 2021 Aug; 54(4):547-556. PubMed ID: 34023234
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 40.